Cipla Shares Jump 4% as Citi Forecasts Major Growth Catalysts

Cipla's stock witnessed a significant rally on Monday, hitting a high of Rs 1,409 on the BSE, following a bullish update from international brokerage firm Citi. The Wall Street firm has placed the pharmaceutical major on a "90-day Positive Catalyst Watch," maintaining a ‘Buy’ rating with a target price of Rs 1,700, suggesting a potential upside of over 25%.

US Market Triggers and Product Approvals

A primary driver behind Citi's optimism is the series of upcoming regulatory and product milestones in the United States. The brokerage highlighted that the likely approval of gFlovent from Cipla's Goa facility could significantly bolster growth in the US market. Furthermore, the expected launch of gVentolin is viewed as a key near-term trigger.

Cipla's performance in the US is also showing signs of a recovery. The company’s Nintedanib has already captured nearly 50% of the market share in the US, and the broader US business is poised for a revenue rebound after a period of recent weakness. Additionally, a pending re-inspection of the Indore plant by the USFDA is expected; a favorable outcome here could serve as a major positive catalyst for investors.

Robust Domestic Performance and Valuation Edge

While the US market offers growth, Cipla’s India business remains a cornerstone of its stability, contributing nearly two-thirds of its EBITDA. Citi noted that the domestic portfolio is performing well, specifically supported by a recovery in its respiratory segment.

From a valuation perspective, Citi argues that Cipla offers a more attractive entry point compared to its domestic-focused peers. While providing significant exposure to the Indian pharmaceutical market, Cipla’s India business is valued at 7.8 times FY26 sales, which is more reasonable than Mankind Pharma, which trades at 8.5 times. The brokerage also noted that easing geopolitical tensions are helping to stabilize raw material costs, which should support margins.

The optimism from Citi comes despite a challenging Q4 FY26 for the company. Cipla reported a significant 55% year-on-year decline in consolidated net profit, falling to Rs 555 crore from Rs 1,222 crore in the same quarter last year. Revenue from operations also saw a slight dip of approximately 3% YoY to Rs 6,541 crore.

However, Citi believes these earnings have likely "bottomed out" following the impact of gRevlimid. Despite the recent volatility—with shares down over 6% in 2026—the brokerage maintains that the risk-reward profile is favorable, supported by the stock trading at 25x FY27E earnings and 21x FY28E earnings.

Key Takeaways

  • Bullish Target: Citi maintains a ‘Buy’ rating for Cipla with a target price of Rs 1,700, implying a 25.55% upside.
  • US Growth Drivers: Upcoming approvals for gFlovent and the launch of gVentolin, alongside high Nintedanib market share, are critical US catalysts.
  • Attractive Valuation: Cipla provides efficient exposure to the Indian market, trading at a lower sales multiple (7.8x) compared to domestic peers like Mankind.